The effect of age on the efficacy of maintenance bacillus calmette-guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: Results from EORTC genito-urinary group study 30911

European Urology

Volumn 66, Issue 4, 2014, Pages 694-701

  Oddens, Jorg R ^a   Sylvester, Richard J ^b   Brausi, Maurizio A ^c   Kirkels, Wim J ^d   Van De Beek, Cees ^e   Van Andel, George ^f   De Reijke, Theo M ^g   Prescott, Stephen ^h   Witjes, J Alfred ⁱ   Oosterlinck, Willem ^j  

^a JEROEN BOSCH HOSPITAL   (Netherlands)

^b EORTC DATA CENTER   (Belgium)

^c Nuovo Ospedale S Agostino   (Italy)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^f ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

^g ACADEMIC MEDICAL CENTER   (Netherlands)

^h ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

ⁱ RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^j GHENT UNIVERSITY HOSPITAL   (Belgium)

more..

Author keywords

Age; Bacillus Calmette Gu rin; Epirubicin; Instillation therapy; Non muscle invasive bladder cancer

Indexed keywords

BCG VACCINE; EPIRUBICIN; ISONIAZID;

AGE; AGED; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SPECIFIC SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; NON MUSCLE INVASIVE BLADDER CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; TREATMENT OUTCOME; VERY ELDERLY; ADJUVANT CHEMOTHERAPY; CANCER STAGING; CARCINOMA, TRANSITIONAL CELL; CLINICAL TRIAL; COMPARATIVE STUDY; CYSTECTOMY; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG ADMINISTRATION; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PROCEDURES; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SURVIVAL RATE; TUMOR INVASION; TUMOR RECURRENCE; URINARY BLADDER NEOPLASMS; ADULT; BCG VACCINATION; CANCER MORTALITY; CANCER PATIENT; CANCER RISK; CANCER SURVIVAL; CANCER THERAPY; DISTANT METASTASIS; HIGH RISK PATIENT; MUSCLE INVASIVE BLADDER CANCER; RECURRENT DISEASE; TRANSURETHRAL RESECTION; TREATMENT DURATION;

AGE FACTORS; AGED; AGED, 80 AND OVER; BCG VACCINE; CARCINOMA, TRANSITIONAL CELL; CHEMOTHERAPY, ADJUVANT; CYSTECTOMY; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EPIRUBICIN; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 84908356401     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2014.05.033     Document Type: Article

References (24)

1. R.J. Sylvester, A.P.M. van der Meijden, and W. Oosterlinck et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials Eur Urol 49 2006 466 477
2. M. Babjuk, M. Burger, and R. Zigeuner et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013 Eur Urol 64 2013 639 653
3. P.-U. Malmström, R.J. Sylvester, and D.E. Crawford et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette- Guérin for non-muscle-invasive bladder cancer Eur Urol 56 2009 247 256
4. R.J. Sylvester, A.P. van der Meijden, and D.L. Lamm Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials J Urol 168 2002 1964 1970
5. A. Böhle, and P.R. Bock Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression Urology 63 2004 682 686
6. M.D. Shelley, M.D. Mason, and H. Kynaston Intravesical therapy for superficial bladder cancer: a systematic review of randomised trials and meta-analyses Cancer Treat Rev 36 2010 195 205
7. R.J. Sylvester, M.A. Brausi, and W.J. Kirkels et al. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder Eur Urol 57 2010 766 773
8. A.P. van der Meijden, M. Brausi, and V. Zambon et al. Intravesical instillation of epirubicin, bacillus Calmette-Guérin and bacillus Calmette-Guérin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer Genito-Urinary Group randomized phase III trial J Urol 166 2001 476 481
9. J.G. Heiner, and M.K. Terris Effect of advanced age on the development of complications from intravesical bacillus Calmette-Guérin therapy Urol Oncol 26 2008 137 140
10. E.C. De Boer, W.H. De Jong, and P.A. Steerenberg et al. Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guérin in superficial bladder cancer Cancer Immunol Immunother 34 1992 306 312
11. T.M. de Reijke, E.C. de Boer, and K.H. Kurth et al. Urinary cytokines during intravesical bacillus Calmette-Guérin therapy for superficial bladder cancer: processing, stability and prognostic value J Urol 155 1996 477 482
12. Y. Shintani, Y. Sawada, and T. Inagaki et al. Intravesical instillation therapy with bacillus Calmette-Guérin for superficial bladder cancer: study of the mechanism of bacillus Calmette-Guérin immunotherapy Int J Urol 14 2007 140 146
13. I.C. Roberts-Thomson, S. Whittingham, and U. Youngchaiyud et al. Ageing, immune response, and mortality Lancet 2 1974 368 370
14. G. Pfister, and W. Savino Can the immune system still be efficient in the elderly? An immunological and immunoendocrine therapeutic perspective Neuroimmunomodulation 15 2008 351 364
15. C.F. Lynch, and M.B. Cohen Urinary system Cancer. 75 Suppl 1995 316 329
16. L.H. Sobin, and C. Wittekind TNM classification of malignant tumors (UICC) ed. 5 1997 Wiley Liss New York, NY p. 107-90
17. F.N. Joudi, B.J. Smith, and M.A. O'Donnell et al. The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy J Urol 175 2006 1634 1639
18. H.W. Herr Age and outcome of superficial bladder cancer treated with bacille Calmette-Guérin therapy Urology 70 2007 65 68
19. F. Saint, N. Kurth, P. Maille, and D. Vordos et al. Urinary IL-2 assay for monitoring intravesical bacillus Calmette-Guérin response of superficial bladder cancer during induction course and maintenance therapy Int J Cancer 107 2003 434 440
20. D. Margel, S.S. Alkhateeb, A. Finelli, and N. Fleshner Diminished efficacy of Bacille Calmette-Guérin among elderly patients with nonmuscle invasive bladder cancer Urology 78 2011 848 854
21. J. Fernandez-Gomez, R. Madero, and E. Solsona et al. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guérin: the CUETO scoring model J Urol 182 2009 2195 2203
22. A. Ojea, J.L. Nogueira, and E. Solsona et al. A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C Eur Urol 52 2007 1398 1406
23. J. Oddens, M. Brausi, and R. Sylvester et al. Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance Eur Urol 63 2013 462 472
24. J.A. Taylor III, and G.A. Kuchel Bladder cancer in the elderly: clinical outcomes, basic mechanisms, and future research direction Nat Clin Pract Urol 6 2009 135 144